These results indicate that higher levels of specific immune cells and pathways, including aDCs, T cell co-stimulation, APC co-inhibition, CCR, parainflammation, Tfh, Th1, Th2, Type I IFN Response, Treg, TIL, inflammation-promoting, T cell co-inhibition, and CD8 + T cells, along with lower levels of B cells, neutrophils, HLA, DCs, Type II IFN Response, pDCs, mast cells, iDCs, and NK cells, are associated with poorer prognosis in ccRCC patients (Fig. S7). The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.